Endocrine Therapy in Breast Cancer

Jan G. M. Klijn, Els M. J. J. Berns, and John A. Foekens Panel Discussion 1: Advanced Breast Cancer Manfred Kaufmann and Henning T. Mouridsen Early Breast Cancer Early Breast Cancer: Tamoxifen Overview Carsten Rose Aromatase Inhibitors and Early Breast Cancer Paul E. Goss SERMs: Overview in Early Breast Cancer Ian E. Smith Surrogate and Intermediate Markers in Early Breast Cancer Mitch Dowsett Panel Discussion 2: Early Breast Cancer Hans-Jorg Senn and William R. Miller Neoadjuvant Therapy Neoadjuvant Endocrine Therapy for Breast Cancer: A Medical Oncologist's Perspective Matthew J. Ellis Neoadjuvant Therapy: Surgical Perspectives J. Michael Dixon Pathology of Breast Cancer Following Neoadjuvant Endocrine Therapy Hironobu Sasano, Takashi Suzuki, and Takuya Moriya Neoadjuvant Therapy: Prediction of Response William R. Miller, T. J. Anderson, S. Iqbal, and J. Michael Dixon Mechanisms of Resistance to Endocrine Therapy Nancy E. Hynes Panel Discussion 3: Neoadjuvant Therapy James N. Ingle and Ian E. Smith Chemoprevention Epidemiological Basis of Hormonal Chemoprevention of Breast Cancer Malcolm C. Pike, John R. Daniels, and Darcy V. Spicer Breast Carcinogenesis and Its Prevention by Inhibition of Estrogen Genotoxicity Joachim G. Liehr Use of Selective Antiestrogens for the Chemoprevention of Breast Cancer Trevor J. Powles Aromatase Inhibitors and Chemoprevention of Breast Cancer Paul E. Goss Panel Discussion 4: Chemoprevention Christopher C. Benz and Anthony Howell Conclusion Panel Discussion 5: Final Discussion and Wrap-Up James N. Ingle and Ajay Bhatnagar Index This reference evaluates and describes the latest strategies for hormone suppression and blockade in the management of early and advanced stage breast cancer and explores the effects of tamoxifen, selective estrogen receptor modulators (SERMs), aromatase inhibitors, and their combination on both breast cancers and normal tissues. Endocrine Therapy in Breast Cancer details modern techniques for molecular profiling, monitoring, and targeting offers methods to identify high-risk groups evaluates molecular biomarkers in breast cancer assessment examines the potential toxicity of estrogen receptor (ER)-directed endocrine therapy investigates the development of endocrine resistance discusses neoadjuvant and preoperative approaches in patient care reviews mechanisms that lead to estrogen-independent phenotypes Surveying the medical, surgical, and pathological aspects of endocrine therapy, as well as future research opportunities, Endocrine Therapy in Breast Cancer is a concise and in-depth manual for medical, surgical, and radiation oncologists; endocrinologists; gynecologists; obstetricians; pharmacologists; family physicians; reproductive biologists; epidemiologists; and medical school students.James N. Ingle is the author of 'Endocrine Therapy in Breast Cancer', published 2002 under ISBN 9780824707873 and ISBN 0824707877.